Nov 16, 2021 | AIMS-2-TRIALS News
AIMS-2-TRIALS researchers, in partnership with ethicists at the University of Oxford and scientists at McGill University, have reviewed the ethics surrounding ‘early autism research’. This field of research identifies early changes in the developing brain (so-called...
Jul 5, 2021 | AIMS-2-TRIALS News
Infants with more of the genetic differences related to autism were found to respond to faces differently, even at a very young age, before signs of autism might be noticeable. Many thanks to Birkbeck for allowing us to reprint this article about AIMS-2-TRIALS...
Jul 1, 2021 | AIMS-2-TRIALS News
AIMS-2-TRIALS researchers are working alongside autistic people to develop technology that objectively measures aspects of their experience. Wearable devices, such as smart watches, can include sensors to record information like heart rate and skin conductivity and...
Jun 28, 2021 | AIMS-2-TRIALS News
Innovation Radar is a European Commission initiative to identify innovations and innovators in EU-funded research. AIMS-2-TRIALS recently submitted several important developments to the scheme, receiving positive feedback and inclusion within the Innovation Radar...
May 19, 2021 | AIMS-2-TRIALS News
Our news item published on May 19th 2021 highlighted ways that the COVID-19 pandemic has exacerbated existing healthcare inequalities for autistic people. We now report on a recently-published systematic review that aimed to identify the broader range of healthcare...
May 18, 2021 | AIMS-2-TRIALS News
According to a new AIMS-2-TRIALS study published today in BMJ OPEN, the COVID-19 pandemic has further exacerbated existing healthcare inequalities for autistic people and has likely contributed to disproportionate increases in morbidity and mortality, mental health/...
